Govt should roll out comprehensive National Cancer Care Policy with dedicated funding outlay: FICCI-EY Parthenon Report: Our ...

Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis: Oslo, Norway Tuesday, November 12, 2024, 18:00 Hrs ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced it is pledging $7.8 million to the ‘Fund our Futures’ campaign led by ...

ALIGNMT AI, a leading provider of software solutions for AI governance and compliance, announced a strategic collaboration with the Healthcare Financial Management Association (HFMA) to launch a ...

STEERLife, a pioneer in pharmaceutical development technologies, and Callidus Research Laboratories, a formulation development services company with a wealth of experience in comprehensive ...

Oversimplification about integration of traditional & modern treatment systems creates confusion: Dr Kotecha: Peethaambaran ...

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...

Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European ...

Chicago, Illinois Tuesday, November 12, 2024, 14:00 Hrs [IST] ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...

Two exclusive conferences focusing on "Reference Material (RM) Producers" organized by National Accreditation Board for Testing and Calibration Laboratories (NABL) are scheduled to be held on January ...

The Directorate General of Trade Remedies (DGTR), under the ministry of commerce and industry, has released a list of registered interested parties regarding the ongoing Second Sunset Review ...